MeSH term
Frequency | Condition_Probility | Animals | 368 | 0.0 |
Humans | 1135 | 0.0 |
Oligonucleotide Array Sequence Analysis | 8 | 0.0 |
Cell Culture Techniques | 3 | 0.0 |
Cell Differentiation/*physiology | 3 | 1.0 |
Treatment Outcome | 3 | 0.0 |
CDC2-CDC28 Kinases/genetics/*metabolism | 4 | 100.0 |
Cells, Cultured | 108 | 0.0 |
Cyclin A/genetics/*metabolism | 2 | 66.0 |
DNA Damage | 15 | 1.0 |
*DNA Repair | 4 | 0.0 |
DNA-Binding Proteins/genetics/metabolism | 4 | 0.0 |
Gamma Rays | 4 | 1.0 |
*Gene Expression Regulation | 11 | 0.0 |
Hematopoietic Stem Cells | 2 | 3.0 |
Macromolecular Substances | 39 | 2.0 |
Male | 114 | 0.0 |
Mice | 173 | 0.0 |
Mice, Inbred BALB C | 12 | 0.0 |
Mice, Knockout | 12 | 0.0 |
Promoter Regions (Genetics) | 20 | 0.0 |
Protein p53/genetics/metabolism | 7 | 7.0 |
Recombination, Genetic | 3 | 0.0 |
Research Support, Non-U.S. Gov't | 788 | 0.0 |
Two-Hybrid System Techniques | 7 | 0.0 |
Ultraviolet Rays | 4 | 0.0 |
Adenoviridae/genetics | 9 | 1.0 |
Apoptosis | 33 | 1.0 |
Bromodeoxyuridine/pharmacology | 6 | 11.0 |
CDC2-CDC28 Kinases/metabolism | 35 | 81.0 |
Cell Cycle | 120 | 10.0 |
Cell Differentiation | 18 | 0.0 |
Cell Line, Tumor | 55 | 1.0 |
Cell Proliferation | 5 | 2.0 |
Cyclin-Dependent Kinases/*physiology | 22 | 45.0 |
Dyes/pharmacology | 4 | 4.0 |
G1 Phase | 84 | 26.0 |
Immunoblotting | 42 | 1.0 |
Immunohistochemistry | 52 | 0.0 |
Ki-67 Antigen/biosynthesis | 3 | 3.0 |
Mice, Transgenic | 10 | 0.0 |
Proto-Oncogene Proteins/*physiology | 2 | 0.0 |
RNA, Messenger/metabolism | 28 | 0.0 |
RNA, Small Interfering/metabolism | 3 | 1.0 |
Research Support, U.S. Gov't, P.H.S. | 451 | 0.0 |
S Phase | 62 | 18.0 |
Time Factors | 85 | 0.0 |
Transgenes | 2 | 0.0 |
Amino Acid Sequence | 117 | 0.0 |
*CDC2-CDC28 Kinases | 564 | 83.0 |
Cyclin E/physiology | 9 | 90.0 |
Hela Cells | 94 | 1.0 |
Molecular Sequence Data | 143 | 0.0 |
Phosphorylation | 290 | 3.0 |
*Promoter Regions (Genetics) | 3 | 0.0 |
Protein-Serine-Threonine Kinases/*physiology | 21 | 16.0 |
*Transcription, Genetic | 10 | 0.0 |
Blotting, Western | 139 | 2.0 |
Breast Neoplasms/*metabolism/pathology | 8 | 4.0 |
Cyclin-Dependent Kinases/*antagonists & inhibitors | 72 | 53.0 |
*Down-Regulation | 2 | 0.0 |
Enzyme Inhibitors/*pharmacology | 45 | 6.0 |
Tumor Cells, Cultured | 389 | 2.0 |
Animals, Newborn | 2 | 0.0 |
Hematopoietic Stem Cells/*metabolism | 3 | 2.0 |
Myeloid Cells/*metabolism | 2 | 12.0 |
Protein Processing, Post-Translational | 7 | 0.0 |
Substrate Specificity | 38 | 1.0 |
CDC2 Protein Kinase/*metabolism | 13 | 12.0 |
Cyclin-Dependent Kinases/*metabolism | 132 | 50.0 |
Electrophoresis, Polyacrylamide Gel | 19 | 0.0 |
Enzyme Activation | 68 | 1.0 |
Proliferating Cell Nuclear Antigen/metabolism | 15 | 7.0 |
Protein-Serine-Threonine Kinases/*metabolism | 107 | 15.0 |
Adenosine Triphosphate/metabolism | 9 | 2.0 |
Catalysis | 7 | 0.0 |
Comparative Study | 69 | 0.0 |
Cyclin A/*metabolism | 16 | 41.0 |
Histones/metabolism | 21 | 8.0 |
Kinetics | 70 | 0.0 |
Models, Biological | 37 | 1.0 |
Protein Binding | 88 | 1.0 |
Recombinant Fusion Proteins/metabolism | 17 | 1.0 |
Cell Cycle Proteins/metabolism | 47 | 13.0 |
Cell-Free System | 4 | 1.0 |
Cyclin A/*physiology | 5 | 71.0 |
Cyclin E/*physiology | 3 | 42.0 |
*DNA Replication | 11 | 4.0 |
Nuclear Proteins/metabolism | 15 | 1.0 |
Apoptosis/*drug effects | 45 | 5.0 |
Cell Cycle/drug effects | 92 | 17.0 |
Cell Division/*drug effects | 26 | 8.0 |
Cyclin-Dependent Kinases/*antagonists & inhibitors/metabolism | 27 | 67.0 |
Cyclins/metabolism | 109 | 27.0 |
Gene Expression | 46 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/*metabolism | 5 | 2.0 |
Purines/*pharmacology | 14 | 82.0 |
Tumor Cells, Cultured/drug effects/metabolism | 7 | 3.0 |
Antineoplastic Agents, Phytogenic/*pharmacology | 14 | 8.0 |
Catechin/analogs & derivatives/*pharmacology | 2 | 40.0 |
Drug Screening Assays, Antitumor | 15 | 4.0 |
Neoplasm Invasiveness | 6 | 0.0 |
Acetylcysteine/*analogs & derivatives/pharmacology | 4 | 9.0 |
*Cell Adhesion | 2 | 1.0 |
Cyclins/genetics/*metabolism | 21 | 25.0 |
Cysteine Endopeptidases/metabolism | 9 | 3.0 |
Cysteine Proteinase Inhibitors/pharmacology | 7 | 3.0 |
Down-Regulation | 37 | 1.0 |
Mitogen-Activated Protein Kinases/metabolism | 14 | 1.0 |
Multienzyme Complexes/antagonists & inhibitors/metabolism | 2 | 9.0 |
Mutation | 51 | 0.0 |
Proteasome Endopeptidase Complex | 17 | 3.0 |
Signal Transduction | 56 | 0.0 |
Tumor Suppressor Proteins/metabolism | 24 | 21.0 |
Ubiquitin/metabolism | 7 | 3.0 |
*Cell Cycle Proteins | 189 | 15.0 |
Cell Line | 164 | 0.0 |
Fibroblasts/virology | 2 | 12.0 |
Gene Products, tat/*metabolism | 2 | 2.0 |
Plasmids | 6 | 0.0 |
Positive Transcriptional Elongation Factor B | 3 | 5.0 |
Protein Kinases/*metabolism | 22 | 6.0 |
RNA Polymerase II/chemistry/*metabolism | 3 | 15.0 |
Crystallization | 4 | 1.0 |
Crystallography, X-Ray | 31 | 3.0 |
Cyclin-Dependent Kinases/*chemistry/*metabolism | 3 | 75.0 |
Protein-Serine-Threonine Kinases/*chemistry/*metabolism | 4 | 17.0 |
*Apoptosis | 34 | 2.0 |
Base Sequence | 78 | 0.0 |
Cell Cycle/physiology | 21 | 6.0 |
Flow Cytometry | 85 | 1.0 |
Heat-Shock Proteins 70/metabolism | 2 | 3.0 |
Protein p53/*genetics | 3 | 1.0 |
Rats | 78 | 0.0 |
Sequence Homology, Nucleic Acid | 7 | 0.0 |
CDK9 Protein Kinase | 2 | 2.0 |
Cell Differentiation/physiology | 3 | 0.0 |
Cyclins/*physiology | 24 | 47.0 |
Cycloheximide/pharmacology | 8 | 1.0 |
Precipitin Tests | 59 | 2.0 |
Protein Synthesis Inhibitors/pharmacology | 8 | 2.0 |
Transcription, Genetic/*physiology | 2 | 1.0 |
Adult | 50 | 0.0 |
Aged | 51 | 0.0 |
Aged, 80 and over | 20 | 0.0 |
Apoptosis/*genetics | 5 | 2.0 |
Cyclin-Dependent Kinases/genetics | 7 | 12.0 |
DNA, Neoplasm/analysis | 4 | 0.0 |
Female | 176 | 0.0 |
Middle Aged | 62 | 0.0 |
Neoplasm Proteins/genetics | 4 | 0.0 |
Polymerase Chain Reaction/methods | 5 | 0.0 |
*Proto-Oncogene Proteins | 170 | 10.0 |
*Saccharomyces cerevisiae Proteins | 13 | 1.0 |
Transcription Factors/genetics | 3 | 0.0 |
Cell Cycle Proteins/physiology | 5 | 13.0 |
Cell Division/physiology | 38 | 4.0 |
Enzyme Activation/physiology | 6 | 3.0 |
Fibroblasts/cytology/enzymology | 3 | 8.0 |
Mitogens/physiology | 2 | 11.0 |
Antineoplastic Agents/pharmacology | 15 | 2.0 |
Apigenin | 2 | 18.0 |
Cell Cycle/*drug effects | 66 | 38.0 |
Cell Division/drug effects | 147 | 4.0 |
Cell Survival/drug effects | 19 | 1.0 |
Flavonoids/*pharmacology | 8 | 10.0 |
NF-kappa B/*metabolism | 2 | 0.0 |
Prostatic Neoplasms/metabolism/*pathology | 5 | 7.0 |
Protein p53/metabolism | 32 | 5.0 |
Proto-Oncogene Proteins/*metabolism | 5 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 94 | 0.0 |
Retinoblastoma Protein/metabolism | 124 | 35.0 |
Cyclin A/*biosynthesis | 5 | 55.0 |
Cyclin-Dependent Kinases/biosynthesis | 19 | 61.0 |
Neoplasm Staging | 10 | 0.0 |
Protein-Serine-Threonine Kinases/biosynthesis | 15 | 50.0 |
Survival Rate | 7 | 0.0 |
*DNA-Binding Proteins | 52 | 3.0 |
Receptor Protein-Tyrosine Kinases/genetics | 2 | 1.0 |
Reverse Transcriptase Polymerase Chain Reaction | 21 | 0.0 |
Cisplatin/*pharmacology | 2 | 1.0 |
Cyclin A/metabolism | 40 | 51.0 |
Cyclin-Dependent Kinases/metabolism | 166 | 47.0 |
Drug Synergism | 13 | 0.0 |
Protein-Serine-Threonine Kinases/metabolism | 150 | 17.0 |
Tretinoin/*pharmacology | 9 | 2.0 |
Carrier Proteins/genetics/metabolism | 2 | 1.0 |
Cloning, Molecular | 33 | 0.0 |
Escherichia coli/metabolism | 2 | 0.0 |
Protein Isoforms | 7 | 1.0 |
*Protein Kinases | 5 | 7.0 |
Sequence Alignment | 20 | 0.0 |
Cattle | 18 | 0.0 |
Cell Cycle/*physiology | 45 | 15.0 |
Cyclins/*metabolism | 93 | 33.0 |
DNA Polymerase III/*metabolism | 2 | 16.0 |
DNA-Binding Proteins/metabolism | 17 | 0.0 |
Cell Differentiation/genetics | 5 | 1.0 |
Gene Expression Regulation | 25 | 0.0 |
Cell Cycle Proteins/*physiology | 7 | 13.0 |
Cell Division | 100 | 2.0 |
Cell Nucleus/metabolism | 24 | 1.0 |
DNA | 2 | 0.0 |
Mammals | 5 | 1.0 |
RNA, Messenger/biosynthesis | 8 | 0.0 |
Tissue Distribution | 6 | 0.0 |
Xenopus | 15 | 2.0 |
*Xenopus Proteins | 3 | 0.0 |
Cell Cycle Proteins/*analysis | 3 | 16.0 |
Cyclin D1/analysis | 4 | 10.0 |
Cyclin E/analysis | 6 | 40.0 |
Cyclin-Dependent Kinases/analysis | 7 | 41.0 |
*Intracellular Signaling Peptides and Proteins | 5 | 0.0 |
Protein p16/analysis | 3 | 15.0 |
Protein-Serine-Threonine Kinases/analysis | 8 | 44.0 |
Tumor Markers, Biological/analysis | 2 | 0.0 |
Tumor Suppressor Proteins/analysis | 3 | 23.0 |
Cyclin-Dependent Kinases/genetics/*metabolism | 22 | 35.0 |
Cyclins/genetics/metabolism | 13 | 22.0 |
Enzyme Inhibitors/metabolism | 37 | 17.0 |
Human T-lymphotropic virus 1/*metabolism | 2 | 10.0 |
Protein Structure, Tertiary | 21 | 0.0 |
Protein-Serine-Threonine Kinases/genetics/metabolism | 8 | 7.0 |
Retinoblastoma Protein/*metabolism | 45 | 24.0 |
Antineoplastic Agents/*pharmacology | 57 | 5.0 |
Carcinoma, Squamous Cell/*genetics/pathology | 2 | 3.0 |
Cyclin-Dependent Kinases/*biosynthesis | 13 | 40.0 |
*DNA Damage | 14 | 2.0 |
DNA, Complementary | 8 | 0.0 |
Fibroblasts | 18 | 3.0 |
Genes, cdc | 4 | 8.0 |
In Situ Nick-End Labeling | 7 | 1.0 |
Point Mutation | 7 | 0.0 |
Transplantation, Heterologous | 10 | 1.0 |
Antibodies, Monoclonal/*pharmacology | 3 | 1.0 |
Breast Neoplasms/metabolism/*pathology | 7 | 8.0 |
Cell Cycle Proteins/*metabolism | 34 | 10.0 |
Cell Membrane/metabolism | 2 | 0.0 |
Cyclin E/antagonists & inhibitors | 2 | 100.0 |
G1 Phase/*drug effects | 50 | 64.0 |
Gene Expression Regulation, Neoplastic/*drug effects | 15 | 5.0 |
Protein-Serine-Threonine Kinases/antagonists & inhibitors | 27 | 27.0 |
Tumor Suppressor Proteins/*metabolism | 13 | 13.0 |
4-Butyrolactone/*analogs & derivatives/pharmacology | 3 | 50.0 |
Blotting, Northern | 36 | 0.0 |
DNA, Complementary/metabolism | 8 | 0.0 |
DNA-Binding Proteins/*metabolism | 8 | 0.0 |
Enzyme Inhibitors/pharmacology | 49 | 1.0 |
Luciferases/metabolism | 6 | 0.0 |
Plasmids/metabolism | 14 | 1.0 |
Protein Kinase Inhibitors/pharmacology | 3 | 15.0 |
RNA/metabolism | 3 | 0.0 |
Tetrazolium Salts/pharmacology | 5 | 9.0 |
Thiazoles/pharmacology | 5 | 4.0 |
Transcription Factors/*metabolism | 24 | 1.0 |
Binding Sites | 51 | 0.0 |
CHO Cells | 6 | 0.0 |
G2 Phase | 14 | 8.0 |
Hamsters | 13 | 0.0 |
Ligases/genetics/*metabolism | 2 | 4.0 |
Mitosis | 23 | 5.0 |
Protein-Serine-Threonine Kinases/genetics/*metabolism | 17 | 7.0 |
Recombinant Fusion Proteins/genetics/metabolism | 17 | 1.0 |
Sequence Homology, Amino Acid | 29 | 0.0 |
Serine/metabolism | 9 | 2.0 |
Ubiquitin/*metabolism | 3 | 1.0 |
Cyclin D1/metabolism | 28 | 19.0 |
Cyclin E/metabolism | 68 | 59.0 |
Protein Kinases/metabolism | 32 | 7.0 |
*Protein-Serine-Threonine Kinases | 46 | 5.0 |
Temperature | 6 | 0.0 |
Transforming Growth Factor beta/*pharmacology | 26 | 6.0 |
Analysis of Variance | 3 | 0.0 |
Cell Cycle/*drug effects/genetics | 2 | 40.0 |
HL-60 Cells/drug effects | 2 | 9.0 |
Molecular Biology | 3 | 1.0 |
Phosphorylation/drug effects | 42 | 5.0 |
CDC2 Protein Kinase/metabolism | 38 | 24.0 |
Cell Survival | 10 | 0.0 |
Colonic Neoplasms/pathology | 3 | 5.0 |
Cyclin B/metabolism | 11 | 11.0 |
Cyclin D1/*metabolism | 10 | 16.0 |
DNA Fragmentation | 11 | 3.0 |
Multienzyme Complexes/metabolism | 8 | 4.0 |
Pancreatic Neoplasms/pathology | 2 | 11.0 |
Apoptosis/drug effects | 28 | 4.0 |
Colony-Forming Units Assay | 3 | 0.0 |
DNA, Neoplasm/drug effects | 3 | 9.0 |
Dose-Response Relationship, Drug | 73 | 1.0 |
Protein-Serine-Threonine Kinases/*antagonists & inhibitors/metabolism | 13 | 39.0 |
Tumor Cells, Cultured/drug effects/enzymology | 3 | 9.0 |
Signal Transduction/*physiology | 2 | 0.0 |
*Centrosome | 3 | 37.0 |
Indoles/*pharmacology | 7 | 7.0 |
Cell Proliferation/drug effects | 5 | 6.0 |
G1 Phase/physiology | 18 | 24.0 |
Rats, Sprague-Dawley | 8 | 0.0 |
S Phase/physiology | 16 | 21.0 |
*Apoptosis/radiation effects | 3 | 42.0 |
Caspases/metabolism | 20 | 3.0 |
Cyclin E/chemistry/*metabolism | 2 | 100.0 |
Cyclin-Dependent Kinases/chemistry/metabolism | 3 | 60.0 |
Dose-Response Relationship, Radiation | 4 | 1.0 |
Molecular Weight | 16 | 0.0 |
Mutagenesis, Site-Directed | 25 | 0.0 |
Recombinant Proteins | 4 | 0.0 |
Amino Acid Motifs | 10 | 1.0 |
Cyclin A/chemistry/metabolism | 2 | 100.0 |
Models, Molecular | 37 | 1.0 |
Peptide Fragments/chemistry/metabolism | 4 | 3.0 |
Peptide Mapping | 15 | 3.0 |
Protein Conformation | 20 | 0.0 |
Trypsin/metabolism | 2 | 1.0 |
Cell Cycle/drug effects/physiology | 9 | 17.0 |
DNA/biosynthesis | 22 | 3.0 |
Embryonic and Fetal Development/physiology | 2 | 2.0 |
Mitosis/drug effects/physiology | 2 | 16.0 |
Nuclear Proteins/*metabolism | 8 | 1.0 |
Signal Transduction/drug effects/*physiology | 3 | 1.0 |
Carcinoma, Hepatocellular/*metabolism | 2 | 1.0 |
DNA, Neoplasm/*metabolism | 2 | 6.0 |
Liver Neoplasms/*metabolism | 4 | 4.0 |
Transfection | 130 | 1.0 |
Amino Acid Chloromethyl Ketones/pharmacology | 3 | 2.0 |
Caspases/antagonists & inhibitors/metabolism | 2 | 2.0 |
Mitogen-Activated Protein Kinase Kinases/metabolism | 3 | 1.0 |
Mitogens/pharmacology | 3 | 1.0 |
Prostatic Neoplasms/enzymology/*metabolism/pathology | 2 | 16.0 |
Protein-Tyrosine Kinase/antagonists & inhibitors/metabolism | 2 | 3.0 |
Signal Transduction/drug effects | 18 | 2.0 |
p38 Mitogen-Activated Protein Kinases | 4 | 0.0 |
Calcitriol/*analogs & derivatives/*pharmacology | 2 | 16.0 |
Cyclins/biosynthesis | 17 | 17.0 |
Intracellular Membranes/metabolism | 2 | 1.0 |
MAP Kinase Signaling System | 4 | 1.0 |
Membrane Potentials/drug effects | 3 | 2.0 |
Proto-Oncogene Proteins/biosynthesis | 3 | 1.0 |
*Proto-Oncogene Proteins c-bcl-2 | 6 | 1.0 |
Up-Regulation | 30 | 1.0 |
Adenocarcinoma/genetics/*pathology | 2 | 9.0 |
Cyclins/analysis/physiology | 2 | 100.0 |
Genes, p53 | 9 | 1.0 |
Lung Neoplasms/genetics/*pathology | 2 | 13.0 |
Nocodazole/pharmacology | 6 | 4.0 |
*Cyclin-Dependent Kinases | 59 | 31.0 |
Hydrogen Bonding | 7 | 3.0 |
Structure-Activity Relationship | 47 | 1.0 |
Antineoplastic Agents/chemical synthesis/pharmacology | 3 | 33.0 |
Enzyme Inhibitors/chemical synthesis/pharmacology | 4 | 36.0 |
Inhibitory Concentration 50 | 15 | 5.0 |
Cell Cycle Proteins/genetics/*metabolism | 7 | 5.0 |
DNA-Binding Proteins/genetics/*metabolism | 9 | 0.0 |
Gene Expression/drug effects | 9 | 1.0 |
Interleukin-4/*pharmacology | 2 | 0.0 |
Phosphoproteins/genetics/*metabolism | 3 | 1.0 |
*Drug Design | 4 | 4.0 |
8-Bromo Cyclic Adenosine Monophosphate/pharmacology | 5 | 5.0 |
Amino Acid Substitution | 7 | 0.0 |
Breast Neoplasms/*pathology | 6 | 2.0 |
Cell Cycle Proteins/genetics | 4 | 4.0 |
Epidermal Growth Factor/pharmacology | 9 | 1.0 |
Genes, Tumor Suppressor/drug effects | 3 | 50.0 |
Mice, Nude | 24 | 1.0 |
Mitogen-Activated Protein Kinase 1/metabolism | 6 | 1.0 |
Mitogen-Activated Protein Kinase 3 | 9 | 1.0 |
Recombinant Proteins/chemistry/metabolism | 4 | 0.0 |
*Gene Expression Profiling | 4 | 0.0 |
*Gene Expression Regulation, Neoplastic | 15 | 1.0 |
Genes, Tumor Suppressor | 14 | 1.0 |
Colonic Neoplasms/*metabolism | 2 | 2.0 |
RNA Processing, Post-Transcriptional | 4 | 3.0 |
Transforming Growth Factor beta/*metabolism | 5 | 2.0 |
Cell Cycle/*drug effects/physiology | 6 | 46.0 |
Cyclin E/drug effects/metabolism | 3 | 60.0 |
Cyclins/drug effects/metabolism | 8 | 44.0 |
Protein p16/drug effects/metabolism | 3 | 100.0 |
Retinoblastoma Protein/drug effects/metabolism | 8 | 47.0 |
*Adaptor Proteins, Signal Transducing | 3 | 0.0 |
*Adaptor Proteins, Vesicular Transport | 2 | 0.0 |
Anticarcinogenic Agents/*pharmacology | 10 | 11.0 |
Carcinoma, Squamous Cell/*metabolism/pathology | 4 | 4.0 |
Cell Cycle Proteins/biosynthesis | 8 | 30.0 |
Receptor, Epidermal Growth Factor/antagonists & inhibitors | 2 | 5.0 |
Silymarin/*pharmacology | 6 | 35.0 |
Tumor Suppressor Proteins/biosynthesis | 4 | 25.0 |
G1 Phase/drug effects | 45 | 43.0 |
G2 Phase/drug effects | 7 | 14.0 |
Mitosis/drug effects | 7 | 6.0 |
*Monoterpenes | 2 | 20.0 |
Terpenes/*pharmacology | 2 | 10.0 |
COS Cells | 13 | 0.0 |
Cyclin A/genetics/metabolism | 5 | 71.0 |
Cyclin E/genetics/metabolism | 4 | 40.0 |
Cyclins/chemistry/genetics/*metabolism | 4 | 57.0 |
DNA, Complementary/genetics | 9 | 0.0 |
In Vitro | 21 | 0.0 |
Recombinant Proteins/genetics/metabolism | 11 | 1.0 |
Serine/chemistry | 3 | 2.0 |
Cell Division/drug effects/physiology | 16 | 5.0 |
Cyclin A/biosynthesis | 4 | 28.0 |
Half-Life | 6 | 1.0 |
Enzyme Inhibitors/*metabolism | 17 | 21.0 |
Nuclear Proteins/biosynthesis | 2 | 4.0 |
Phenotype | 14 | 0.0 |
Prognosis | 20 | 0.0 |
Diterpenes/*pharmacology | 2 | 6.0 |
K562 Cells | 5 | 1.0 |
Models, Chemical | 8 | 2.0 |
Protein Kinase C/*metabolism | 4 | 1.0 |
Protein-Serine-Threonine Kinases/*antagonists & inhibitors | 25 | 51.0 |
cdc25 Phosphatase/metabolism | 8 | 15.0 |
Breast Neoplasms/*metabolism | 9 | 3.0 |
Cyclin D1/biosynthesis | 7 | 17.0 |
Estradiol/*analogs & derivatives/pharmacology | 3 | 6.0 |
Fibroblasts/metabolism | 8 | 0.0 |
Immunoprecipitation | 2 | 0.0 |
Proteins/metabolism | 13 | 1.0 |
S-Phase Kinase-Associated Proteins/*metabolism | 2 | 22.0 |
Cell Cycle Proteins/genetics/metabolism | 5 | 7.0 |
Cyclin D1/genetics/*metabolism | 6 | 30.0 |
Transcription Factors/genetics/metabolism | 4 | 0.0 |
Transforming Growth Factor beta/metabolism | 2 | 1.0 |
Carcinoma, Non-Small-Cell Lung/*pathology | 2 | 8.0 |
Enzyme-Linked Immunosorbent Assay | 2 | 0.0 |
Lung Neoplasms/*pathology | 3 | 4.0 |
NF-kappa B/metabolism | 4 | 0.0 |
Signal Transduction/physiology | 13 | 1.0 |
Antineoplastic Agents/*chemical synthesis/chemistry/pharmacology | 3 | 10.0 |
Enzyme Inhibitors/*chemical synthesis/chemistry/pharmacology | 7 | 21.0 |
S Phase/drug effects | 16 | 27.0 |
Cyclin E/*biosynthesis | 7 | 87.0 |
HT29 Cells | 7 | 3.0 |
S Phase/*drug effects | 7 | 38.0 |
DNA, Neoplasm/biosynthesis | 6 | 5.0 |
Genes, Reporter | 15 | 0.0 |
Luciferases/genetics | 4 | 1.0 |
RNA, Messenger/genetics | 18 | 0.0 |
Receptors, Estrogen/genetics | 2 | 3.0 |
Trans-Activation (Genetics)/drug effects | 3 | 1.0 |
Caspases/*metabolism | 5 | 2.0 |
Cell Line, Transformed | 32 | 2.0 |
Carrier Proteins/metabolism | 9 | 1.0 |
Cyclin-Dependent Kinases/*antagonists & inhibitors/*metabolism | 11 | 84.0 |
Drug Resistance | 5 | 0.0 |
Protein p53/pharmacology | 2 | 33.0 |
Centrosome/*metabolism/ultrastructure | 2 | 40.0 |
Cyclin-Dependent Kinases/genetics/metabolism | 5 | 17.0 |
Nucleic Acid Synthesis Inhibitors/pharmacology | 3 | 2.0 |
Oxazoles/pharmacology | 2 | 5.0 |
Paclitaxel/pharmacology | 7 | 7.0 |
Phosphoprotein Phosphatase/*metabolism | 3 | 3.0 |
Cell Count | 3 | 0.0 |
Cell Death/drug effects | 4 | 2.0 |
Cyclin-Dependent Kinases/drug effects/metabolism | 8 | 53.0 |
Protein-Serine-Threonine Kinases/drug effects/metabolism | 6 | 35.0 |
Camptothecin/*analogs & derivatives/pharmacology | 2 | 20.0 |
Cisplatin/pharmacology | 3 | 1.0 |
Fluorouracil/pharmacology | 2 | 3.0 |
Gene Expression Regulation, Enzymologic/drug effects | 4 | 2.0 |
Quinazolines/pharmacology | 2 | 2.0 |
RNA, Messenger/drug effects/genetics/metabolism | 2 | 2.0 |
Cyclin-Dependent Kinases/physiology | 12 | 44.0 |
Gene Deletion | 5 | 0.0 |
Neoplasms/genetics | 2 | 1.0 |
Cyclin E/antagonists & inhibitors/metabolism | 2 | 66.0 |
Leukemia, Myeloid/*metabolism/pathology | 2 | 11.0 |
Cyclin E/*genetics | 4 | 80.0 |
Retinoblastoma Protein/physiology | 7 | 20.0 |
Recombinant Fusion Proteins/genetics/isolation & purification/metabolism | 2 | 5.0 |
Spectrum Analysis, Mass | 5 | 0.0 |
Spodoptera | 16 | 5.0 |
Threonine | 5 | 8.0 |
Xenopus laevis | 4 | 0.0 |
Carcinoma, Squamous Cell/pathology | 2 | 4.0 |
G1 Phase/*drug effects/physiology | 6 | 60.0 |
Stilbenes/*pharmacology | 5 | 9.0 |
Adenocarcinoma/pathology | 2 | 2.0 |
Lung Neoplasms/pathology | 4 | 7.0 |
Proto-Oncogene Proteins/metabolism | 13 | 1.0 |
Proto-Oncogene Proteins c-bcl-2/metabolism | 10 | 2.0 |
Quinazolines/*pharmacology | 3 | 3.0 |
Apoptosis/drug effects/physiology | 2 | 2.0 |
HCT116 Cells | 3 | 13.0 |
Purines/pharmacology | 28 | 49.0 |
Acetamides/*pharmacology | 2 | 16.0 |
Drug Design | 8 | 2.0 |
Mitosis/*drug effects | 5 | 10.0 |
Tumor Suppressor Proteins/*physiology | 2 | 6.0 |
Neoplasms/*drug therapy | 2 | 1.0 |
14-3-3 Proteins | 3 | 2.0 |
Transcription, Genetic | 28 | 0.0 |
Cell Transformation, Neoplastic/*drug effects | 2 | 5.0 |
English Abstract | 15 | 0.0 |
Cell Cycle Proteins/*biosynthesis | 10 | 23.0 |
Cyclin E/biosynthesis | 4 | 50.0 |
Pregnancy | 5 | 0.0 |
Transcription Factors/biosynthesis | 4 | 4.0 |
DNA Mutational Analysis | 6 | 0.0 |
Protein p16/*metabolism | 4 | 12.0 |
*Tumor Suppressor Proteins | 156 | 11.0 |
Casein Kinase II | 4 | 3.0 |
Cyclins/physiology | 16 | 40.0 |
Mitomycin/pharmacology | 2 | 2.0 |
Protein p53/*physiology | 5 | 4.0 |
Carrier Proteins/biosynthesis/genetics/*physiology | 2 | 15.0 |
In Situ Hybridization, Fluorescence | 5 | 0.0 |
Protein-Tyrosine Kinase/*metabolism | 3 | 0.0 |
Tyrosine/metabolism | 7 | 0.0 |
Adolescent | 8 | 0.0 |
Disease Progression | 10 | 0.0 |
Follow-Up Studies | 3 | 0.0 |
Protein-Serine-Threonine Kinases/*biosynthesis | 11 | 36.0 |
Cyclin-Dependent Kinases/*chemistry/metabolism | 4 | 66.0 |
Peptides/chemistry/metabolism | 3 | 6.0 |
Autoradiography | 4 | 0.0 |
DNA/metabolism | 10 | 0.0 |
Cytochrome c Group/metabolism | 2 | 1.0 |
Cytoplasm/metabolism | 10 | 1.0 |
Cytosol/metabolism | 4 | 0.0 |
Doxorubicin/pharmacology | 7 | 3.0 |
Microscopy, Fluorescence | 15 | 0.0 |
Mitochondria/metabolism | 4 | 1.0 |
*Mitosis | 3 | 2.0 |
Protein Transport | 2 | 0.0 |
Endometrial Neoplasms/*metabolism/pathology | 2 | 6.0 |
Proto-Oncogene Proteins c-fos/biosynthesis/genetics | 2 | 16.0 |
Receptors, Progesterone | 2 | 20.0 |
Protein p16/biosynthesis | 3 | 15.0 |
Retinoblastoma Protein/biosynthesis | 5 | 21.0 |
Colon/metabolism/pathology | 2 | 13.0 |
Cyclin-Dependent Kinases/immunology/*metabolism | 2 | 66.0 |
Disease-Free Survival | 2 | 0.0 |
Hyperplasia | 3 | 0.0 |
Immunoenzyme Techniques | 10 | 0.0 |
Ki-67 Antigen/metabolism | 7 | 3.0 |
Lymphatic Metastasis | 9 | 0.0 |
Protein-Serine-Threonine Kinases/immunology/*metabolism | 2 | 40.0 |
Up-Regulation/drug effects | 11 | 3.0 |
Enzyme Inhibitors/*chemical synthesis/*pharmacology | 5 | 35.0 |
Xenograft Model Antitumor Assays | 3 | 1.0 |
Carcinoma, Non-Small-Cell Lung | 2 | 10.0 |
Drug Resistance, Neoplasm | 10 | 1.0 |
Lung Neoplasms | 5 | 4.0 |
Sulfonamides/*pharmacology | 2 | 4.0 |
Binding Sites/genetics | 5 | 0.0 |
Interphase | 3 | 1.0 |
Trans-Activation (Genetics) | 13 | 0.0 |
Cyclin D1/*biosynthesis | 2 | 10.0 |
Cohort Studies | 2 | 0.0 |
Proliferating Cell Nuclear Antigen/analysis | 4 | 1.0 |
*Protein Biosynthesis | 4 | 0.0 |
Survival Analysis | 7 | 0.0 |
Breast/*cytology/drug effects | 2 | 66.0 |
Epithelial Cells/metabolism | 2 | 0.0 |
Cell Differentiation/drug effects | 14 | 1.0 |
Gene Expression Regulation/drug effects | 13 | 1.0 |
Genes, cdc/*drug effects | 2 | 50.0 |
HL-60 Cells | 13 | 2.0 |
Tetradecanoylphorbol Acetate/pharmacology | 9 | 0.0 |
Threonine/metabolism | 4 | 4.0 |
Breast Neoplasms/enzymology/*pathology | 2 | 15.0 |
*Drug Resistance, Neoplasm | 3 | 1.0 |
Estrogen Receptor Modulators/*pharmacology | 2 | 8.0 |
Mitogen-Activated Protein Kinases/antagonists & inhibitors/*metabolism | 3 | 3.0 |
Breast Neoplasms/drug therapy | 2 | 6.0 |
Cell Separation | 5 | 0.0 |
Ligands | 11 | 0.0 |
Receptors, Cytoplasmic and Nuclear/*metabolism | 3 | 2.0 |
Antineoplastic Agents/therapeutic use | 3 | 1.0 |
Phosphoproteins/*metabolism | 5 | 1.0 |
*Proteins | 18 | 4.0 |
*Cell Transformation, Neoplastic | 3 | 0.0 |
Cyclin-Dependent Kinases/antagonists & inhibitors | 27 | 35.0 |
Histone Deacetylases/*antagonists & inhibitors | 3 | 6.0 |
Microfilament Proteins/physiology | 2 | 33.0 |
*Muscle Proteins | 16 | 5.0 |
Oncogene Proteins, Viral/*physiology | 4 | 11.0 |
Cell Cycle Proteins/*biosynthesis/genetics | 2 | 12.0 |
Cyclin-Dependent Kinases/biosynthesis/genetics | 5 | 50.0 |
Cyclins/biosynthesis/genetics | 8 | 16.0 |
Depression, Chemical | 2 | 1.0 |
Genes, bcl-2 | 2 | 1.0 |
Interleukin-7/*pharmacology | 2 | 4.0 |
Neoplasm Proteins/*biosynthesis/genetics | 4 | 2.0 |
Oligonucleotides, Antisense/pharmacology | 5 | 1.0 |
Proto-Oncogene Proteins c-bcl-2/biosynthesis/genetics | 2 | 4.0 |
Growth Inhibitors/pharmacology | 9 | 6.0 |
Imidazoles/*pharmacology | 3 | 4.0 |
Molecular Conformation | 9 | 3.0 |
Apoptosis/physiology | 5 | 1.0 |
Gene Therapy/*methods | 3 | 0.0 |
Poly(ADP-ribose) Polymerases/metabolism | 8 | 6.0 |
Transduction, Genetic | 4 | 1.0 |
*Alternative Splicing | 5 | 0.0 |
Cercopithecus aethiops | 7 | 0.0 |
Cyclin E/*metabolism | 24 | 61.0 |
Cyclin-Dependent Kinases/*genetics/metabolism | 4 | 33.0 |
Cyclins | 3 | 30.0 |
Enzyme Inhibitors | 9 | 10.0 |
Protein-Serine-Threonine Kinases/*genetics/metabolism | 4 | 6.0 |
Rabbits | 14 | 0.0 |
Cell Cycle/drug effects/*physiology | 16 | 32.0 |
Cyclin-Dependent Kinases/antagonists & inhibitors/metabolism | 27 | 52.0 |
Estradiol/pharmacology | 2 | 0.0 |
Diploidy | 3 | 2.0 |
Phorbol Esters/pharmacology | 2 | 1.0 |
Ploidies | 2 | 0.0 |
Cyclins/*biosynthesis/metabolism | 6 | 75.0 |
Enzyme Induction | 4 | 0.0 |
Transcription Factors/metabolism | 29 | 2.0 |
Glutathione Transferase/metabolism | 11 | 1.0 |
Protein p53/*metabolism | 14 | 2.0 |
*Transcription Factors, TFII | 6 | 5.0 |
Tumor Cells, Cultured/drug effects | 21 | 3.0 |
Cyclin D1/*genetics/metabolism | 3 | 15.0 |
*Drosophila Proteins | 3 | 0.0 |
*Nuclear Proteins | 13 | 0.0 |
RNA, Messenger | 5 | 1.0 |
*Trans-Activation (Genetics) | 4 | 0.0 |
Immediate-Early Proteins/genetics/*metabolism | 2 | 3.0 |
Leupeptins/pharmacology | 6 | 4.0 |
*Protein Processing, Post-Translational | 6 | 2.0 |
Subcellular Fractions/*metabolism | 2 | 10.0 |
Alkaline Phosphatase/metabolism | 2 | 1.0 |
Caco-2 Cells | 6 | 1.0 |
Down-Regulation/drug effects | 5 | 1.0 |
Cyclin-Dependent Kinases/*genetics | 14 | 21.0 |
Gene Expression Regulation, Neoplastic | 24 | 1.0 |
Polymorphism, Single-Stranded Conformational | 2 | 0.0 |
Protein-Serine-Threonine Kinases/*genetics | 12 | 4.0 |
RNA, Messenger/genetics/metabolism | 12 | 0.0 |
DNA-Binding Proteins/*genetics/*metabolism | 2 | 1.0 |
Gene Expression Profiling | 4 | 0.0 |
Gene Expression Regulation/*drug effects | 3 | 0.0 |
Transcription Factors/*genetics/*metabolism | 2 | 1.0 |
Antineoplastic Agents, Phytogenic/pharmacology | 3 | 3.0 |
Biological Assay | 2 | 0.0 |
Antineoplastic Agents/chemistry/pharmacology | 2 | 18.0 |
Hydroxyurea/pharmacology | 5 | 9.0 |
Phosphothreonine/metabolism | 6 | 14.0 |
Protein-Tyrosine-Phosphatase/chemistry | 2 | 50.0 |
CDC2 Protein Kinase/*genetics | 6 | 18.0 |
Gene Expression Regulation/*physiology | 3 | 0.0 |
3T3 Cells | 37 | 1.0 |
Green Fluorescent Proteins | 3 | 0.0 |
Tetracycline/pharmacology | 4 | 5.0 |
Carcinoma/*metabolism/pathology | 3 | 4.0 |
Thyroid Neoplasms/*metabolism/pathology | 2 | 4.0 |
*Transforming Growth Factor beta | 2 | 1.0 |
Gene Expression Regulation, Enzymologic | 6 | 0.0 |
Neoplasm Transplantation | 10 | 0.0 |
Prostatic Neoplasms/*metabolism/pathology | 3 | 3.0 |
RNA, Messenger/analysis | 14 | 0.0 |
Receptors, Androgen/*metabolism | 2 | 1.0 |
Apoptosis/drug effects/*physiology | 4 | 1.0 |
Culture Media | 5 | 0.0 |
Gene Expression Regulation, Neoplastic/drug effects | 20 | 4.0 |
Mitogen-Activated Protein Kinases/*metabolism | 6 | 1.0 |
Pancreatic Neoplasms/*pathology | 2 | 5.0 |
Proto-Oncogene Proteins c-bcl-2/genetics | 2 | 1.0 |
DNA Replication | 21 | 5.0 |
Herpesvirus 1, Human/genetics/*physiology | 2 | 13.0 |
Nuclear Proteins/genetics/metabolism | 2 | 1.0 |
Retinoblastoma Protein/genetics/metabolism | 5 | 14.0 |
Vero Cells | 2 | 0.0 |
Adenocarcinoma/metabolism/*pathology | 2 | 3.0 |
Culture Media, Serum-Free/pharmacology | 2 | 1.0 |
Cyclins/*metabolism/*physiology | 2 | 66.0 |
Fetal Blood/physiology | 4 | 17.0 |
Neoplasm Proteins/*metabolism | 6 | 1.0 |
Phosphoproteins/metabolism | 8 | 1.0 |
Protein Processing, Post-Translational/drug effects | 12 | 10.0 |
Sequence Deletion | 12 | 0.0 |
Tumor Cells, Cultured/metabolism | 2 | 1.0 |
Purines/chemistry/*pharmacology | 2 | 100.0 |
Protein Biosynthesis | 9 | 0.0 |
Apoptosis/*physiology | 13 | 1.0 |
Breast Neoplasms | 12 | 4.0 |
CDC2 Protein Kinase/antagonists & inhibitors/*metabolism | 3 | 42.0 |
Colonic Neoplasms | 2 | 1.0 |
Pancreatic Neoplasms | 2 | 5.0 |
Prostatic Neoplasms | 2 | 3.0 |
Cell Transformation, Neoplastic | 11 | 1.0 |
Cyclin D1/genetics/metabolism | 3 | 12.0 |
Staurosporine/metabolism/*pharmacology | 2 | 66.0 |
Cell Cycle/genetics/*physiology | 2 | 10.0 |
Fungal Proteins/genetics/*metabolism | 2 | 3.0 |
Nuclear Proteins/genetics/*metabolism | 4 | 1.0 |
Infant, Newborn | 3 | 0.0 |
Multienzyme Complexes/physiology | 2 | 8.0 |
DNA Primers | 11 | 0.0 |
G1 Phase/*physiology | 22 | 47.0 |
Microtubule-Associated Proteins/metabolism | 33 | 23.0 |
Cyclins/analysis/metabolism | 2 | 33.0 |
Staurosporine/analogs & derivatives | 7 | 28.0 |
Binding Sites/physiology | 2 | 1.0 |
Microtubule-Associated Proteins/genetics/*metabolism | 12 | 30.0 |
Protein Binding/physiology | 4 | 1.0 |
Cyclin E/*analysis | 6 | 66.0 |
Cyclins/*analysis | 6 | 15.0 |
Interleukin-3/pharmacology | 2 | 0.0 |
Microtubule-Associated Proteins/*analysis | 3 | 14.0 |
Stem Cell Factor/pharmacology | 2 | 1.0 |
CDC2 Protein Kinase/biosynthesis | 6 | 54.0 |
*G1 Phase | 21 | 43.0 |
Microtubule-Associated Proteins/biosynthesis | 3 | 17.0 |
Proteins/*physiology | 2 | 1.0 |
*S Phase | 11 | 16.0 |
Cyclin D1/biosynthesis/genetics | 3 | 15.0 |
Cyclin E/*biosynthesis/genetics | 2 | 50.0 |
Cyclin-Dependent Kinases/*biosynthesis/genetics | 4 | 80.0 |
Cyclins/*biosynthesis/genetics | 12 | 34.0 |
Protein-Serine-Threonine Kinases/*biosynthesis/genetics | 2 | 8.0 |
RNA, Messenger/biosynthesis/genetics | 5 | 0.0 |
Cyclin D1/antagonists & inhibitors | 2 | 66.0 |
Phosphotransferases/metabolism | 4 | 8.0 |
Hydroxamic Acids/*pharmacology | 2 | 4.0 |
Protein p53/physiology | 7 | 8.0 |
Carrier Proteins/*metabolism | 6 | 0.0 |
S-Phase Kinase-Associated Proteins | 6 | 8.0 |
Alkaloids/*pharmacology | 9 | 16.0 |
DNA, Neoplasm/metabolism | 6 | 4.0 |
Proto-Oncogene Proteins c-bcl-2/biosynthesis | 2 | 1.0 |
*Transcription Factors | 4 | 0.0 |
Electrophoresis, Agar Gel | 3 | 0.0 |
*Carrier Proteins | 43 | 7.0 |
*Cell Aging | 7 | 12.0 |
Mutagenesis | 4 | 0.0 |
Retinoblastoma Protein/genetics/*metabolism | 4 | 9.0 |
Estrogens/*metabolism | 3 | 5.0 |
Enzyme Inhibitors/*chemistry/pharmacology | 2 | 33.0 |
Antibiotics, Antineoplastic/*pharmacology | 2 | 1.0 |
Cyclins/*antagonists & inhibitors | 2 | 50.0 |
Doxorubicin/*pharmacology | 3 | 4.0 |
X-Rays | 3 | 2.0 |
*Signal Transduction | 10 | 0.0 |
CDC2-CDC28 Kinases/*metabolism | 15 | 88.0 |
Oncogene Proteins/metabolism | 7 | 8.0 |
Ovarian Neoplasms | 3 | 8.0 |
Recombinant Proteins/metabolism | 26 | 1.0 |
Promoter Regions (Genetics)/*genetics | 2 | 0.0 |
Species Specificity | 4 | 0.0 |
Transcription, Genetic/*drug effects | 3 | 0.0 |
G1 Phase/*radiation effects | 2 | 40.0 |
Radiation, Ionizing | 6 | 4.0 |
Flavonoids/chemistry/*pharmacology | 3 | 23.0 |
Gene Expression Regulation, Enzymologic/*drug effects | 2 | 1.0 |
Melanoma/*pathology | 5 | 9.0 |
Annexin A5/metabolism | 2 | 2.0 |
Cyclin-Dependent Kinases/antagonists & inhibitors/*metabolism | 31 | 62.0 |
Microtubule-Associated Proteins/*metabolism | 26 | 24.0 |
Protein-Serine-Threonine Kinases/antagonists & inhibitors/*metabolism | 23 | 31.0 |
Stomach Neoplasms/*metabolism | 2 | 4.0 |
Active Transport, Cell Nucleus/physiology | 2 | 3.0 |
Cell Nucleus/*metabolism | 7 | 1.0 |
DNA Replication/physiology | 3 | 9.0 |
Nuclear Proteins/chemistry/*metabolism | 3 | 5.0 |
Protein-Serine-Threonine Kinases/chemistry/metabolism | 2 | 20.0 |
Cyclins/genetics/*physiology | 2 | 20.0 |
G1 Phase/genetics | 3 | 10.0 |
*Genes, Tumor Suppressor | 5 | 0.0 |
Protein p53/genetics/physiology | 2 | 8.0 |
MAP Kinase Signaling System/*drug effects | 3 | 7.0 |
Tumor Markers, Biological/*metabolism | 4 | 0.0 |
Alleles | 2 | 0.0 |
Cell Cycle/*genetics/radiation effects | 2 | 28.0 |
Protein Kinases/genetics/*physiology | 3 | 18.0 |
Jurkat Cells | 10 | 0.0 |
Antineoplastic Agents, Hormonal/*pharmacology | 2 | 3.0 |
Dexamethasone/*pharmacology | 4 | 1.0 |
Genistein/*pharmacology | 5 | 15.0 |
beta-Galactosidase/metabolism | 3 | 1.0 |
Blotting, Southern | 6 | 0.0 |
Cell Transformation, Viral | 6 | 2.0 |
Mice, SCID | 2 | 0.0 |
Cell Aging/*physiology | 6 | 11.0 |
DNA/genetics/metabolism | 3 | 0.0 |
*Gene Expression Regulation, Enzymologic/drug effects | 2 | 4.0 |
Mutation/genetics | 5 | 0.0 |
Promoter Regions (Genetics)/genetics | 10 | 0.0 |
Response Elements/genetics | 2 | 1.0 |
Clone Cells | 5 | 0.0 |
DNA Primers/genetics | 4 | 0.0 |
G1 Phase/genetics/physiology | 2 | 40.0 |
Genes, Dominant | 4 | 0.0 |
*Mutation | 12 | 0.0 |
S Phase/genetics/*physiology | 2 | 33.0 |
Chromones/pharmacology | 3 | 1.0 |
Microtubule-Associated Proteins/biosynthesis/*physiology | 2 | 66.0 |
Morpholines/pharmacology | 3 | 1.0 |
Protein-Serine-Threonine Kinases/physiology | 6 | 6.0 |
Signal Transduction/drug effects/physiology | 8 | 3.0 |
Up-Regulation/physiology | 2 | 1.0 |
Cyclin E/genetics/*metabolism | 3 | 42.0 |
Cell Division/*physiology | 3 | 1.0 |
Protamine Kinase/metabolism | 10 | 43.0 |
Cyclin A/analysis | 4 | 33.0 |
Cyclin-Dependent Kinases/*analysis | 7 | 36.0 |
Protein-Serine-Threonine Kinases/*analysis | 5 | 38.0 |
Reference Values | 6 | 0.0 |
Protein p16/biosynthesis/genetics | 2 | 20.0 |
Protein-Serine-Threonine Kinases/biosynthesis/genetics | 7 | 58.0 |
Transcription Factors/biosynthesis/genetics/*metabolism | 2 | 11.0 |
Cytomegalovirus/*physiology | 2 | 7.0 |
Cell Cycle Proteins/drug effects/metabolism | 2 | 14.0 |
Cyclin A/genetics | 3 | 27.0 |
Rats, Inbred F344 | 2 | 0.0 |
DNA-Binding Proteins/*physiology | 6 | 1.0 |
Organ Specificity | 6 | 0.0 |
Trans-Activators/*physiology | 3 | 1.0 |
U937 Cells/metabolism | 2 | 50.0 |
Polymerase Chain Reaction | 19 | 0.0 |
Signal Transduction/genetics | 3 | 1.0 |
Mitosis/physiology | 4 | 4.0 |
Plasmids/genetics/metabolism | 3 | 15.0 |
S Phase/drug effects/*physiology | 2 | 50.0 |
Ubiquitins/metabolism | 3 | 2.0 |
cdc25 Phosphatase/*metabolism | 3 | 7.0 |
Neoplasm Proteins/metabolism | 4 | 1.0 |
Nitric Oxide/*metabolism | 2 | 1.0 |
Carcinoma, Hepatocellular/*pathology | 2 | 4.0 |
Cyclin-Dependent Kinases/*pharmacology | 2 | 66.0 |
Liver Neoplasms/*pathology | 2 | 3.0 |
CDC2 Protein Kinase/antagonists & inhibitors | 10 | 62.0 |
*Gene Expression Regulation/drug effects | 2 | 1.0 |
Genes, Reporter/genetics | 4 | 1.0 |
Protein Binding/drug effects | 6 | 1.0 |
Zinc Fingers | 2 | 0.0 |
Proto-Oncogene Proteins c-myc/genetics | 2 | 3.0 |
Cell Cycle Proteins/metabolism/*physiology | 2 | 13.0 |
Prostatic Neoplasms/*pathology | 8 | 6.0 |
Neoplasm Metastasis | 2 | 0.0 |
U937 Cells | 5 | 1.0 |
Cysteine Endopeptidases/*metabolism | 5 | 2.0 |
Genes, myc | 3 | 1.0 |
Interferon Alfa-2b/*pharmacology | 3 | 13.0 |
Multienzyme Complexes/*metabolism | 3 | 2.0 |
Protease Inhibitors/pharmacology | 3 | 1.0 |
Proto-Oncogene Proteins c-myc/metabolism | 7 | 7.0 |
Isoenzymes/genetics/*physiology | 2 | 22.0 |
Protein Kinase C/genetics/*physiology | 2 | 100.0 |
DNA/genetics | 7 | 0.0 |
Interferon-alpha/*pharmacology | 5 | 3.0 |
Codon, Terminator | 2 | 3.0 |
Embryonic and Fetal Development | 2 | 0.0 |
Mice, Inbred C57BL | 3 | 0.0 |
Mice, Mutant Strains | 2 | 0.0 |
Catechin/*analogs & derivatives/*pharmacology | 2 | 8.0 |
MAP Kinase Signaling System/drug effects | 2 | 2.0 |
Plant Extracts/pharmacology | 2 | 5.0 |
Receptor, Epidermal Growth Factor/physiology | 2 | 2.0 |
*Cell Cycle | 45 | 20.0 |
*Gene Therapy | 2 | 0.0 |
Microtubule-Associated Proteins/*biosynthesis/genetics | 7 | 53.0 |
Lovastatin/pharmacology | 4 | 11.0 |
Fluorescent Antibody Technique | 8 | 0.0 |
Breast Neoplasms/metabolism/pathology | 2 | 5.0 |
Cyclins/genetics | 13 | 8.0 |
Protein p16 | 12 | 8.0 |
Receptors, Estrogen/metabolism | 6 | 2.0 |
Antineoplastic Agents/*toxicity | 5 | 7.0 |
Cytoprotection/drug effects | 2 | 20.0 |
Doxorubicin/toxicity | 3 | 14.0 |
Colorectal Neoplasms | 2 | 7.0 |
Antibiotics, Antineoplastic/pharmacology | 2 | 2.0 |
Trans-Activators/metabolism | 3 | 0.0 |
Transcription, Genetic/physiology | 2 | 1.0 |
Cells, Cultured/drug effects | 3 | 3.0 |
Epithelial Cells/*drug effects | 2 | 15.0 |
Staurosporine/*pharmacology | 3 | 15.0 |
Caffeine/*pharmacology | 2 | 10.0 |
Cyclins/metabolism/*physiology | 4 | 40.0 |
Oncogene Proteins, Viral/genetics | 2 | 5.0 |
Phosphodiesterase Inhibitors/*pharmacology | 2 | 4.0 |
Protein p53/metabolism/*physiology | 2 | 16.0 |
*Repressor Proteins | 9 | 0.0 |
Signal Transduction/*drug effects | 7 | 1.0 |
*Cell Differentiation | 2 | 0.0 |
Baculoviridae/genetics | 5 | 3.0 |
Consensus Sequence/genetics | 2 | 4.0 |
Phosphopeptides/analysis | 2 | 10.0 |
Ceramides/*pharmacology | 2 | 10.0 |
Fibroblasts/cytology/drug effects/metabolism | 2 | 3.0 |
Phosphoprotein Phosphatase/metabolism | 3 | 4.0 |
*Enzyme Inhibitors | 5 | 12.0 |
Epithelial Cells/cytology/drug effects | 2 | 8.0 |
Fungal Proteins/metabolism | 5 | 3.0 |
Protein Kinase Inhibitors | 8 | 6.0 |
Brain Neoplasms/*pathology | 3 | 4.0 |
Cyclins/*genetics | 13 | 9.0 |
Glioblastoma/*pathology | 2 | 7.0 |
Insects/cytology | 2 | 16.0 |
Pyrimidines/*chemical synthesis/chemistry/pharmacology | 5 | 22.0 |
Protein Isoforms/genetics | 2 | 0.0 |
Sensitivity and Specificity | 6 | 0.0 |
Cyclin-Dependent Kinases/metabolism/physiology | 2 | 66.0 |
Hematopoietic Stem Cells/*cytology/drug effects | 4 | 5.0 |
Protein-Serine-Threonine Kinases/metabolism/physiology | 2 | 18.0 |
Anticarcinogenic Agents/pharmacology | 2 | 7.0 |
Microtubule-Associated Proteins/physiology | 3 | 21.0 |
G0 Phase | 7 | 10.0 |
Hydroxymethylglutaryl-CoA Reductase Inhibitors/*pharmacology | 3 | 4.0 |
Pyridines/*pharmacology | 2 | 3.0 |
Staurosporine/pharmacology | 6 | 3.0 |
Protein p53/biosynthesis | 4 | 2.0 |
Cell Cycle/genetics | 7 | 4.0 |
Cyclin-Dependent Kinases/antagonists & inhibitors/genetics | 4 | 66.0 |
Cyclins/*genetics/metabolism | 8 | 17.0 |
Genes, Tumor Suppressor/*genetics | 2 | 0.0 |
Microtubule-Associated Proteins/*genetics/metabolism | 2 | 14.0 |
Signal Transduction/*genetics | 2 | 1.0 |
Antineoplastic Agents/chemical synthesis/*pharmacology | 2 | 22.0 |
Carcinoma, Squamous Cell | 3 | 1.0 |
Cyclin B/biosynthesis | 2 | 20.0 |
Antimetabolites, Antineoplastic/*pharmacology | 4 | 4.0 |
Oligonucleotides, Antisense | 2 | 2.0 |
Phenylacetates/*pharmacology | 2 | 28.0 |
Prostatic Neoplasms/*drug therapy/pathology | 4 | 28.0 |
Cyclins/*biosynthesis | 17 | 32.0 |
Flavonoids/pharmacology | 6 | 1.0 |
Piperidines/pharmacology | 3 | 5.0 |
Transcription Factors/*biosynthesis | 3 | 2.0 |
Microtubule-Associated Proteins/*biosynthesis | 3 | 13.0 |
Fibroblasts/cytology/metabolism | 6 | 3.0 |
Transcription Factors/antagonists & inhibitors/genetics/*metabolism | 2 | 13.0 |
CDC2 Protein Kinase/antagonists & inhibitors/metabolism | 2 | 25.0 |
Rats, Wistar | 3 | 0.0 |
Colonic Neoplasms/metabolism | 2 | 3.0 |
*Down-Regulation/drug effects | 2 | 20.0 |
Apoptosis/*drug effects/physiology | 4 | 3.0 |
Fatty Acids, Unsaturated/*pharmacology | 2 | 6.0 |
*Genes, p53 | 3 | 0.0 |
Oncogene Proteins, Viral/genetics/metabolism | 2 | 16.0 |
Indoles/chemistry/*pharmacology | 2 | 18.0 |
Phosphotyrosine/metabolism | 3 | 0.0 |
Porifera/*chemistry | 2 | 25.0 |
Biological Transport | 5 | 0.0 |
Cell Adhesion | 5 | 0.0 |
Microtubule-Associated Proteins/genetics/*physiology | 3 | 50.0 |
1-Phosphatidylinositol 3-Kinase/metabolism | 7 | 1.0 |
Estradiol/*pharmacology | 5 | 2.0 |
Insulin-Like Growth Factor I/*pharmacology | 4 | 2.0 |
Catechin/*analogs & derivatives/pharmacology | 2 | 28.0 |
Cell Fractionation | 5 | 1.0 |
Interleukin-2/*metabolism | 2 | 4.0 |
Microscopy, Confocal | 3 | 0.0 |
T-Lymphocytes/cytology/metabolism | 2 | 7.0 |
Breast Neoplasms/pathology | 5 | 4.0 |
*Genes, Retinoblastoma | 5 | 4.0 |
Cyclin-Dependent Kinases/*antagonists & inhibitors/chemistry | 5 | 71.0 |
Protein-Serine-Threonine Kinases/*antagonists & inhibitors/chemistry | 3 | 75.0 |
Growth Inhibitors/metabolism/pharmacology | 2 | 28.0 |
Papillomavirus, Human/genetics | 2 | 5.0 |
Adenocarcinoma/*pathology | 2 | 2.0 |
Enzyme Activation/drug effects | 23 | 2.0 |
Chromatography, Gel | 7 | 0.0 |
Keratinocytes/metabolism | 2 | 1.0 |
Lactones/pharmacology | 2 | 5.0 |
Lung/metabolism | 3 | 1.0 |
Proteins/genetics/*metabolism | 2 | 0.0 |
Protein Kinase C/*antagonists & inhibitors/metabolism | 2 | 50.0 |
Chromatography, Ion Exchange | 7 | 2.0 |
Protein Isoforms/genetics/metabolism | 3 | 1.0 |
Transcription Factors/genetics/*metabolism | 9 | 1.0 |
Nitriles/pharmacology | 3 | 2.0 |
Cyclin-Dependent Kinases/*chemistry/genetics/*metabolism | 2 | 100.0 |
Protein-Serine-Threonine Kinases/*chemistry/genetics/*metabolism | 2 | 13.0 |
*Threonine | 2 | 10.0 |
Proliferating Cell Nuclear Antigen/*metabolism | 8 | 4.0 |
Carcinoma, Hepatocellular | 3 | 0.0 |
Gene Expression Regulation, Viral | 4 | 1.0 |
Trans-Activators/genetics/*metabolism | 3 | 0.0 |
Cell Division/genetics | 8 | 2.0 |
Embryo | 5 | 1.0 |
Cyclin A/biosynthesis/metabolism | 2 | 100.0 |
Protein-Serine-Threonine Kinases/biosynthesis/metabolism | 3 | 60.0 |
*Ginsenosides | 3 | 33.0 |
Saponins/pharmacology | 2 | 15.0 |
Child | 7 | 0.0 |
Cyclins/chemistry/*metabolism | 3 | 30.0 |
Fluorescent Antibody Technique, Indirect | 7 | 0.0 |
Models, Genetic | 5 | 0.0 |
DNA Replication/drug effects | 9 | 5.0 |
Microfilament Proteins/metabolism | 5 | 5.0 |
NIH 3T3 Cells | 3 | 1.0 |
Neoplasms/metabolism | 2 | 2.0 |
cdc25 Phosphatase/*physiology | 2 | 40.0 |
Stomach Neoplasms | 2 | 6.0 |
Transcription Factors/*genetics/metabolism | 2 | 0.0 |
Age Factors | 2 | 0.0 |
Arsenicals/*pharmacology | 4 | 15.0 |
Oxides/*pharmacology | 4 | 17.0 |
Aorta/cytology | 4 | 5.0 |
*Cell Cycle/drug effects | 3 | 25.0 |
Transcription, Genetic/genetics | 2 | 0.0 |
Embryo/cytology | 3 | 4.0 |
Fibroblasts/cytology/*drug effects | 2 | 16.0 |
Interleukin-1/*pharmacology | 2 | 0.0 |
Protein-Serine-Threonine Kinases/genetics | 5 | 4.0 |
Oncogene Proteins, Viral/genetics/*metabolism | 5 | 17.0 |
Open Reading Frames | 2 | 0.0 |
Genetic Complementation Test | 7 | 1.0 |
Saccharomyces cerevisiae/genetics | 6 | 1.0 |
Oxidative Stress/*physiology | 2 | 2.0 |
S Phase/*physiology | 11 | 22.0 |
*Apoptosis/drug effects | 3 | 2.0 |
Cell Adhesion/drug effects | 4 | 0.0 |
Cell Nucleus/enzymology | 2 | 2.0 |
*Neoplasm Proteins | 3 | 0.0 |
*Tumor Markers, Biological | 2 | 1.0 |
Cyclin-Dependent Kinases/*antagonists & inhibitors/genetics | 2 | 33.0 |
Protein-Serine-Threonine Kinases/antagonists & inhibitors/genetics | 4 | 66.0 |
Transcription, Genetic/drug effects | 7 | 1.0 |
Retinoids/*pharmacology | 3 | 5.0 |
Dimerization | 3 | 0.0 |
Lung Neoplasms/*metabolism | 2 | 2.0 |
Growth Substances/*pharmacology | 2 | 0.0 |
G2 Phase/*drug effects | 5 | 16.0 |
Prostatic Neoplasms/*drug therapy/metabolism/pathology | 2 | 20.0 |
Antineoplastic Agents/*pharmacology/therapeutic use | 3 | 3.0 |
Gene Transfer Techniques | 4 | 0.0 |
*Genes, myc | 4 | 1.0 |
Herpesvirus 4, Human | 2 | 1.0 |
Receptors, Retinoic Acid/*metabolism | 2 | 3.0 |
Antibodies, Monoclonal | 2 | 0.0 |
Receptor, erbB-2/*physiology | 2 | 8.0 |
CDC2 Protein Kinase/analysis/*biosynthesis | 3 | 100.0 |
Cyclin-Dependent Kinases/analysis/*biosynthesis | 2 | 66.0 |
Protein-Serine-Threonine Kinases/analysis/*biosynthesis | 2 | 40.0 |
Risk Factors | 4 | 0.0 |
Iron Chelating Agents/*pharmacology | 2 | 40.0 |
Microtubule-Associated Proteins/pharmacology | 2 | 50.0 |
Recombinant Fusion Proteins | 3 | 0.0 |
Growth Inhibitors/*pharmacology | 9 | 4.0 |
Naphthoquinones/*pharmacology | 2 | 9.0 |
Retinoblastoma Protein/*physiology | 3 | 9.0 |
Transcription Factors/*physiology | 4 | 0.0 |
Antigens, Polyomavirus Transforming/*genetics | 2 | 7.0 |
Disease Models, Animal | 4 | 0.0 |
Antibodies/pharmacology | 3 | 0.0 |
Contact Inhibition/*physiology | 2 | 50.0 |
Umbilical Veins/cytology | 4 | 1.0 |
Wound Healing/physiology | 2 | 3.0 |
Dactinomycin/pharmacology | 3 | 0.0 |
Phosphoproteins/genetics/metabolism | 2 | 2.0 |
Proteins/genetics/metabolism | 2 | 1.0 |
Thymidine/metabolism | 11 | 3.0 |
Tumor Stem Cell Assay | 3 | 1.0 |
Cyclins/antagonists & inhibitors/metabolism | 3 | 100.0 |
Dihydrotestosterone/*pharmacology | 2 | 6.0 |
Protein-Serine-Threonine Kinases/antagonists & inhibitors/metabolism | 9 | 10.0 |
Dimethyl Sulfoxide/pharmacology | 3 | 3.0 |
Microtubule-Associated Proteins/*genetics | 3 | 4.0 |
4-Butyrolactone/analogs & derivatives/pharmacology | 2 | 50.0 |
Chromatin/metabolism | 3 | 1.0 |
Cyclins/*pharmacology | 2 | 18.0 |
Cyclin B/*metabolism | 2 | 6.0 |
Microfilament Proteins/*metabolism | 3 | 4.0 |
*Protein Kinase Inhibitors | 6 | 9.0 |
Genes, cdc/physiology | 3 | 18.0 |
Androstadienes/pharmacology | 2 | 0.0 |
Lovastatin/*pharmacology | 3 | 13.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology | 2 | 0.0 |
Calcitriol/*analogs & derivatives/pharmacology | 3 | 15.0 |
Cell Cycle Proteins/*drug effects/metabolism | 2 | 33.0 |
Cyclin-Dependent Kinases/*drug effects/metabolism | 5 | 100.0 |
Neoplasm Proteins/biosynthesis/genetics | 3 | 2.0 |
Caspases/antagonists & inhibitors/*metabolism | 2 | 3.0 |
Breast Neoplasms/metabolism | 5 | 4.0 |
Cysteine Proteinase Inhibitors/*pharmacology | 2 | 6.0 |
Protein Kinases/genetics/isolation & purification/*metabolism | 2 | 40.0 |
Culture Media, Serum-Free | 6 | 1.0 |
Quinones/*pharmacology | 3 | 9.0 |
Glioma/*metabolism/*pathology | 2 | 20.0 |
DNA Fragmentation/drug effects | 6 | 6.0 |
Neoplasm Proteins/biosynthesis/genetics/*physiology | 3 | 6.0 |
Microfilament Proteins/analysis | 3 | 16.0 |
Protein p16/genetics/*metabolism | 2 | 11.0 |
Blood Proteins/pharmacology | 3 | 6.0 |
Enzyme Activation/drug effects/physiology | 2 | 3.0 |
Skin/cytology | 3 | 1.0 |
Genes, p53/physiology | 2 | 7.0 |
Receptors, Progesterone/metabolism | 2 | 1.0 |
Astrocytes/cytology/drug effects/*metabolism | 2 | 15.0 |
DNA-Binding Proteins/*metabolism/physiology | 2 | 5.0 |
Glioma/*metabolism/pathology | 2 | 7.0 |
*Protein p16 | 8 | 21.0 |
Trans-Activators/*metabolism/physiology | 2 | 12.0 |
Acetylation/drug effects | 2 | 7.0 |
Antibiotics, Peptide/pharmacology | 2 | 7.0 |
Chromatin/*metabolism | 2 | 1.0 |
Histone Deacetylases/antagonists & inhibitors/*metabolism/*pharmacology | 2 | 100.0 |
Histones/genetics/metabolism | 2 | 15.0 |
*Peptides | 2 | 3.0 |
Cyclic AMP/pharmacology/*physiology | 2 | 50.0 |
Cyclic GMP/analogs & derivatives/pharmacology/*physiology | 2 | 50.0 |
Cyclin D1/antagonists & inhibitors/*physiology | 2 | 100.0 |
Muscle, Smooth, Vascular/*cytology/drug effects/metabolism | 2 | 28.0 |
Umbilical Arteries | 2 | 11.0 |
Protein-Serine-Threonine Kinases/*chemistry/metabolism | 3 | 18.0 |
Head and Neck Neoplasms/*drug therapy/metabolism/pathology | 2 | 33.0 |
Recombinant Proteins/antagonists & inhibitors/chemistry | 2 | 25.0 |
*Cell Transformation, Viral | 3 | 1.0 |
Genes, Viral | 2 | 0.0 |
Viral Proteins/genetics/*metabolism | 2 | 3.0 |
Cell Division/drug effects/genetics | 2 | 2.0 |
Dexamethasone/pharmacology | 2 | 0.0 |
Glucocorticoids/*pharmacology | 3 | 1.0 |
Hormone Antagonists/pharmacology | 2 | 3.0 |
Mifepristone/pharmacology | 2 | 2.0 |
Gene Library | 3 | 0.0 |
Microinjections | 5 | 2.0 |
DNA/analysis | 4 | 0.0 |
*Proto-Oncogenes | 2 | 0.0 |
Proto-Oncogene Proteins c-myc/*physiology | 3 | 7.0 |
Calcium/metabolism | 2 | 0.0 |
Lymphocyte Activation/drug effects | 3 | 0.0 |
Epithelial Cells/metabolism/pathology | 2 | 4.0 |
Dyes | 2 | 1.0 |
Indicators and Reagents | 2 | 0.0 |
Tetrazolium Salts | 3 | 5.0 |
Thiazoles | 3 | 5.0 |
Cell Proliferation/*drug effects | 2 | 11.0 |
Combined Modality Therapy | 2 | 0.0 |
Karyotyping | 3 | 0.0 |
Cell Nucleus/chemistry | 2 | 1.0 |
Culture Media/pharmacology | 2 | 2.0 |
Lung | 5 | 5.0 |
Mink | 5 | 7.0 |
Adenosine Triphosphate/*metabolism | 2 | 2.0 |
Genes, Tumor Suppressor/physiology | 2 | 4.0 |
Antibodies, Monoclonal/pharmacology | 4 | 0.0 |
Epidermal Growth Factor/*pharmacology | 3 | 0.0 |
Testosterone Congeners/pharmacology | 2 | 11.0 |
Antigens, Polyomavirus Transforming/metabolism | 2 | 18.0 |
Cell Hypoxia | 2 | 1.0 |
Simian virus 40 | 3 | 6.0 |
Adenocarcinoma | 4 | 3.0 |
IMP Dehydrogenase/*antagonists & inhibitors | 2 | 18.0 |
Drug Evaluation, Preclinical | 3 | 1.0 |
Protein p53/genetics | 3 | 1.0 |
*cdc25 Phosphatase | 9 | 18.0 |
Protein-Tyrosine Kinase/antagonists & inhibitors | 2 | 0.0 |
Receptor, Epidermal Growth Factor/metabolism | 2 | 0.0 |
Antineoplastic Agents/*therapeutic use | 3 | 0.0 |
Clinical Trials | 2 | 0.0 |
Enzyme Inhibitors/*therapeutic use | 3 | 3.0 |
Drug Interactions | 4 | 0.0 |
Molecular Structure | 9 | 1.0 |
Cell Cycle Proteins/biosynthesis/genetics | 2 | 10.0 |
Neoplasm Proteins/*antagonists & inhibitors | 2 | 15.0 |
Receptors, Estrogen/*analysis | 2 | 0.0 |
Tamoxifen/*pharmacology | 2 | 3.0 |
Aphidicolin/pharmacology | 4 | 8.0 |
Mimosine/pharmacology | 2 | 18.0 |
Phosphoserine/metabolism | 2 | 2.0 |
Protein p16/metabolism | 7 | 12.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/metabolism | 6 | 1.0 |
Muscle, Smooth, Vascular/cytology/*drug effects | 2 | 16.0 |
Cervix Neoplasms | 2 | 8.0 |
Growth Inhibitors/*metabolism | 3 | 5.0 |
Phosphates/metabolism | 4 | 4.0 |
*Gene Expression | 7 | 0.0 |
Melanoma/*metabolism | 2 | 3.0 |
Protein-Tyrosine-Phosphatase/metabolism | 3 | 2.0 |
Prostate-Specific Antigen/*biosynthesis | 2 | 20.0 |
Piperidines/*pharmacology | 4 | 7.0 |
Serine/*metabolism | 3 | 3.0 |
Cyclin A/*analysis | 2 | 66.0 |
Ki-67 Antigen/analysis | 4 | 1.0 |
Recombinant Fusion Proteins/chemistry | 2 | 2.0 |
Cyclin D1/antagonists & inhibitors/*metabolism | 2 | 100.0 |
Cyclins/genetics/metabolism/*physiology | 3 | 42.0 |
G1 Phase/drug effects/*physiology | 2 | 50.0 |
Oligopeptides/pharmacology | 2 | 1.0 |
Protein Kinase C/metabolism | 4 | 0.0 |
Proto-Oncogene Proteins c-myc/*metabolism | 4 | 4.0 |
Hypertrophy | 2 | 1.0 |
Osteosarcoma/*metabolism/*pathology | 2 | 50.0 |
Tumor Necrosis Factor-alpha/pharmacology | 7 | 0.0 |
Antibodies | 3 | 0.0 |
Cell Cycle Proteins/chemistry/*metabolism | 2 | 7.0 |
Fibroblasts/cytology/physiology | 3 | 3.0 |
Peptide Fragments/chemistry/immunology | 2 | 3.0 |
Mutagenesis, Insertional | 2 | 0.0 |
Cyclin D1/*genetics | 4 | 6.0 |
Gene Expression Regulation, Neoplastic/*genetics | 2 | 1.0 |
*Mitogen-Activated Protein Kinases | 2 | 0.0 |
Antiviral Agents/*pharmacology | 4 | 2.0 |
In Situ Hybridization | 5 | 0.0 |
Proto-Oncogene Proteins/genetics | 3 | 0.0 |
Purines/*chemistry/*pharmacology | 2 | 100.0 |
Antigens, Nuclear | 2 | 1.0 |
Tumor Markers, Biological/metabolism | 3 | 0.0 |
CDC2 Protein Kinase/*genetics/metabolism | 2 | 28.0 |
Genome, Viral | 2 | 1.0 |
Meiosis | 2 | 1.0 |
Insulin-Like Growth Factor I/pharmacology | 2 | 1.0 |
Oncogene Proteins/*biosynthesis | 4 | 23.0 |
Enzyme Inhibitors/*toxicity | 3 | 25.0 |
Osteosarcoma | 2 | 2.0 |
Cell Death | 2 | 0.0 |
Plants, Medicinal | 2 | 4.0 |
Saponins/*pharmacology | 2 | 20.0 |
Cell Size/drug effects | 2 | 2.0 |
Interleukin-6/*pharmacology | 3 | 1.0 |
Neurons/*cytology | 4 | 6.0 |
Carrier Proteins/genetics | 2 | 0.0 |
Lung Neoplasms/*genetics/pathology | 2 | 2.0 |
Glutathione Transferase | 2 | 4.0 |
Electrophoresis, Gel, Two-Dimensional | 2 | 0.0 |
Carcinoma, Squamous Cell/*metabolism | 2 | 1.0 |
*Photochemotherapy | 2 | 4.0 |
Protein Structure, Secondary | 4 | 0.0 |
Threonine/*metabolism | 3 | 7.0 |
Biological Markers/analysis | 4 | 0.0 |
Cell Size | 4 | 1.0 |
JC Virus/*genetics | 2 | 20.0 |
Immunohistochemistry/methods | 5 | 0.0 |
Lung Neoplasms/metabolism/*pathology | 2 | 5.0 |
Recombinant Fusion Proteins/physiology | 7 | 2.0 |
*Cell Division | 2 | 1.0 |
Nerve Tissue Proteins/metabolism | 2 | 0.0 |
Saccharomyces cerevisiae/enzymology/genetics | 4 | 8.0 |
Microtubule-Associated Proteins/genetics/metabolism | 2 | 10.0 |
Gene Amplification | 3 | 0.0 |
Protein-Tyrosine-Phosphatase/genetics/*metabolism | 3 | 6.0 |
Tyrosine/*metabolism | 2 | 0.0 |
*Gamma Rays | 2 | 4.0 |
Cell Aging | 4 | 4.0 |
RNA, Neoplasm/analysis | 2 | 0.0 |
Recombinant Proteins/biosynthesis | 2 | 0.0 |
CDC2 Protein Kinase/genetics/metabolism | 4 | 26.0 |
PC12 Cells | 2 | 0.0 |
Pheochromocytoma | 2 | 9.0 |
Calcium/pharmacology | 2 | 0.0 |
Cyclin-Dependent Kinases/biosynthesis/*genetics | 2 | 50.0 |
Protein-Serine-Threonine Kinases/biosynthesis/*genetics | 2 | 12.0 |
Apoptosis/genetics | 3 | 1.0 |
Cyclins/biosynthesis/metabolism | 3 | 100.0 |
Gene Silencing | 2 | 0.0 |
RNA, Small Interfering/genetics | 2 | 1.0 |
Cytarabine/*pharmacology | 2 | 5.0 |
Growth Inhibitors/*physiology | 2 | 5.0 |
Protein-Tyrosine Kinase/metabolism | 4 | 0.0 |
Nuclear Proteins/analysis | 2 | 1.0 |
DNA Repair | 4 | 0.0 |
Genes, p53/*genetics | 4 | 1.0 |
Cell Cycle/*radiation effects | 2 | 12.0 |
Enzyme Repression | 2 | 10.0 |
G1 Phase/*genetics | 2 | 9.0 |
*Gene Expression Regulation, Viral | 2 | 0.0 |
Genes, Structural | 3 | 0.0 |
Enzyme Induction/drug effects | 7 | 1.0 |
RNA Polymerase II/metabolism | 3 | 2.0 |
Spodoptera/cytology | 3 | 6.0 |
Bone Neoplasms/pathology | 2 | 12.0 |
Osteosarcoma/pathology | 2 | 11.0 |
Trans-Activators/chemistry/*metabolism | 2 | 3.0 |
Nucleopolyhedrovirus/genetics | 2 | 9.0 |
Proliferating Cell Nuclear Antigen/biosynthesis | 4 | 8.0 |
Binding, Competitive | 5 | 0.0 |
Catalytic Domain | 2 | 0.0 |
Cyclin-Dependent Kinases | 2 | 22.0 |
Protein Folding | 5 | 1.0 |
Adenoviridae/*genetics | 3 | 1.0 |
Oncogene Proteins, Viral/physiology | 2 | 25.0 |
Intestinal Mucosa/*cytology/*physiology | 2 | 100.0 |
Cell Transformation, Neoplastic/genetics | 3 | 1.0 |
Cyclin-Dependent Kinases/metabolism/*physiology | 3 | 33.0 |
Genetic Vectors | 9 | 0.0 |
Tamoxifen/analogs & derivatives/pharmacology | 2 | 7.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/*metabolism | 2 | 0.0 |
Transforming Growth Factor beta/*physiology | 2 | 1.0 |
Growth Inhibitors/metabolism | 2 | 6.0 |
Adenoviruses, Human/genetics | 3 | 6.0 |
Recombinant Proteins/biosynthesis/metabolism | 2 | 1.0 |
Transforming Growth Factor beta/pharmacology | 4 | 1.0 |
Cyclin-Dependent Kinases/genetics/*physiology | 3 | 33.0 |
Platelet-Derived Growth Factor/pharmacology | 2 | 1.0 |
Protein-Serine-Threonine Kinases/genetics/*physiology | 3 | 8.0 |
Microtubule-Associated Proteins/*physiology | 6 | 26.0 |
Oncogene Proteins/chemistry/genetics/*physiology | 2 | 40.0 |
Recombinant Proteins/chemistry/genetics/metabolism | 4 | 1.0 |
Adenocarcinoma/metabolism/pathology | 3 | 5.0 |
Cyclin B/analysis | 2 | 25.0 |
Chromatography, Affinity | 6 | 0.0 |
Conserved Sequence | 7 | 0.0 |
cdc25 Phosphatase | 5 | 10.0 |
Antimetabolites/diagnostic use | 2 | 50.0 |
Bromodeoxyuridine/diagnostic use | 2 | 9.0 |
Cyclin-Dependent Kinases/biosynthesis/genetics/*metabolism | 2 | 66.0 |
Cyclin-Dependent Kinases/biosynthesis/metabolism | 2 | 50.0 |
Cyclins/biosynthesis/*metabolism | 4 | 66.0 |
Hepatocyte Growth Factor/*pharmacology | 2 | 1.0 |
Tumor Cells, Cultured/cytology/drug effects/enzymology | 4 | 25.0 |
B-Lymphocytes/cytology/metabolism | 2 | 11.0 |
Cyclin-Dependent Kinases/chemistry/*metabolism | 3 | 37.0 |
Protein-Serine-Threonine Kinases/chemistry/*metabolism | 4 | 11.0 |
S Phase/drug effects/immunology | 2 | 100.0 |
Cell Cycle Proteins/*drug effects | 2 | 50.0 |
Estrogen Antagonists/*pharmacology | 5 | 7.0 |
Interleukin-2/pharmacology | 2 | 0.0 |
Lymphocyte Activation | 2 | 0.0 |
Phytohemagglutinins/pharmacology | 3 | 0.0 |
Cyclin E/genetics | 3 | 30.0 |
Genes, Fungal | 2 | 1.0 |
Mitotic Index | 3 | 1.0 |
Breast Neoplasms/enzymology/*metabolism | 2 | 16.0 |
Cyclin-Dependent Kinases/biosynthesis/*metabolism | 3 | 75.0 |
Epithelial Cells | 7 | 1.0 |
*Caspases | 3 | 5.0 |
Peptide Fragments/metabolism | 3 | 0.0 |
Mutagenesis/physiology | 2 | 2.0 |
Immunosorbent Techniques | 3 | 1.0 |
Calcitriol/*pharmacology | 6 | 3.0 |
Transcription Factors/*genetics | 2 | 0.0 |
Oocytes/*metabolism | 2 | 5.0 |
RNA/biosynthesis | 2 | 2.0 |
S Phase/genetics | 2 | 9.0 |
Cytoplasm/*metabolism | 2 | 1.0 |
Cyclin D1/physiology | 2 | 40.0 |
CDC2 Protein Kinase/*physiology | 2 | 18.0 |
Cysteine Endopeptidases/*physiology | 2 | 6.0 |
Mice, Inbred C3H | 2 | 0.0 |
Up-Regulation/drug effects/physiology | 3 | 6.0 |
Breast Neoplasms/*drug therapy/pathology | 2 | 5.0 |
Lactones/*pharmacology | 2 | 6.0 |
Tetradecanoylphorbol Acetate/*pharmacology | 4 | 1.0 |
Chromatography, High Pressure Liquid | 4 | 0.0 |
Recombinant Proteins/chemistry/isolation & purification/metabolism | 2 | 2.0 |
Decision Making | 2 | 2.0 |
Antioxidants/pharmacology | 2 | 1.0 |
Protein p53/analysis | 4 | 1.0 |
Adenosine Triphosphate/chemistry | 2 | 8.0 |
Cyclin-Dependent Kinases/*antagonists & inhibitors/*chemistry | 3 | 100.0 |
Protein-Serine-Threonine Kinases/*antagonists & inhibitors/*chemistry | 2 | 100.0 |
Skin | 3 | 4.0 |
*Ultraviolet Rays | 3 | 1.0 |
Carcinoma/*metabolism | 2 | 2.0 |
Endothelium, Vascular/cytology/*drug effects | 2 | 2.0 |
G0 Phase/*drug effects | 4 | 66.0 |
Cell Cycle Proteins/biosynthesis/genetics/*metabolism | 2 | 66.0 |
G1 Phase/drug effects/physiology | 3 | 14.0 |
Tumor Suppressor Proteins/biosynthesis/genetics/*metabolism | 2 | 50.0 |
Chromones/*pharmacology | 2 | 22.0 |
Melanoma | 2 | 2.0 |
Cell Cycle/drug effects/*immunology | 2 | 100.0 |
Sirolimus | 2 | 4.0 |
Chromosome Mapping | 5 | 0.0 |
DNA/*biosynthesis | 4 | 4.0 |
Proteins/*metabolism | 3 | 0.0 |
Cyclins/*genetics/*metabolism | 2 | 40.0 |
Muscle, Smooth, Vascular/cytology/metabolism | 3 | 9.0 |
Swine | 2 | 0.0 |
Burkitt Lymphoma | 4 | 4.0 |
CDC2-CDC28 Kinases/antagonists & inhibitors/*metabolism | 5 | 100.0 |
Cell Transplantation | 2 | 2.0 |
S-Phase Kinase-Associated Proteins/metabolism | 2 | 28.0 |
Tumor Suppressor Proteins/genetics/*metabolism | 6 | 10.0 |
Cyclin-Dependent Kinases/*biosynthesis/genetics/metabolism | 2 | 66.0 |
Exons | 2 | 0.0 |
T-Lymphocytes/*enzymology | 2 | 3.0 |
Cell Cycle/genetics/physiology | 2 | 13.0 |
Cyclin-Dependent Kinases/analysis/metabolism | 3 | 50.0 |
Genes, p53/genetics | 2 | 0.0 |
Protein-Serine-Threonine Kinases/analysis/metabolism | 3 | 75.0 |
*Gene Amplification | 2 | 0.0 |
Protein-Serine-Threonine Kinases/*antagonists & inhibitors/*metabolism | 3 | 60.0 |
Nitriles/*pharmacology | 2 | 8.0 |
Phenols/*pharmacology | 2 | 5.0 |
*Tyrphostins | 4 | 7.0 |
Adenoviridae | 2 | 2.0 |
Protein p53/chemistry/genetics/*metabolism | 2 | 10.0 |
Escherichia coli/genetics | 2 | 0.0 |
Genetic Vectors/genetics | 2 | 0.0 |
Blood | 2 | 1.0 |
Recombinant Proteins/pharmacology | 4 | 0.0 |
Child, Preschool | 3 | 0.0 |
*Genes, p16 | 2 | 2.0 |
Infant | 2 | 0.0 |
G2 Phase/physiology | 3 | 10.0 |
4-Nitroquinoline-1-oxide/*pharmacology | 2 | 100.0 |
Cyclin A/physiology | 2 | 66.0 |
DNA Probes | 4 | 0.0 |
Recombinant Proteins/antagonists & inhibitors/biosynthesis/chemistry | 2 | 40.0 |
Protein-Serine-Threonine Kinases/isolation & purification/*metabolism | 3 | 23.0 |
Protein Kinase C/*physiology | 3 | 3.0 |
1-Phosphatidylinositol 3-Kinase/*metabolism | 2 | 0.0 |
Carcinoma, Hepatocellular/metabolism | 2 | 2.0 |
Cyclin-Dependent Kinases/drug effects/*metabolism | 2 | 50.0 |
Tritium | 2 | 0.0 |
Cell Cycle/*genetics | 7 | 9.0 |
Cyclic AMP/metabolism | 2 | 0.0 |
CDC2 Protein Kinase/*antagonists & inhibitors | 5 | 71.0 |
Cyclin D1 | 32 | 24.0 |
Cyclins/drug effects/genetics/metabolism | 3 | 50.0 |
Microtubule-Associated Proteins/drug effects/metabolism | 2 | 25.0 |
Transcription Factors/physiology | 4 | 1.0 |
Tamoxifen/pharmacology | 2 | 2.0 |
CCAAT-Enhancer-Binding Proteins | 2 | 1.0 |
*Cyclin B | 5 | 45.0 |
Interferon Type II/*pharmacology | 4 | 0.0 |
Enzyme Stability | 2 | 1.0 |
Moths | 3 | 6.0 |
G0 Phase/drug effects | 3 | 20.0 |
Genes, Retinoblastoma | 3 | 3.0 |
Oxidation-Reduction | 3 | 0.0 |
Virus Replication/*drug effects | 2 | 1.0 |
Breast/*cytology | 2 | 5.0 |
Spectrometry, Fluorescence | 2 | 0.0 |
Cell Compartmentation | 2 | 0.0 |
Carcinogens/toxicity | 2 | 3.0 |
Estrogens, Non-Steroidal/*toxicity | 2 | 33.0 |
Oncogene Proteins/biosynthesis | 3 | 30.0 |
Promoter Regions (Genetics)/*physiology | 2 | 2.0 |
Recombinant Fusion Proteins/isolation & purification/metabolism | 2 | 2.0 |
Transcription Factors/isolation & purification/*metabolism | 2 | 3.0 |
Adenovirus E1A Proteins/metabolism | 2 | 6.0 |
Fibroblasts/cytology | 2 | 0.0 |
Cyclins/*chemistry/metabolism | 2 | 40.0 |
Carcinoma, Hepatocellular/pathology | 2 | 4.0 |
*Cyclin A | 2 | 100.0 |
Proto-Oncogene Proteins c-abl/genetics/*metabolism | 2 | 33.0 |
Oncogene Proteins/*metabolism | 2 | 2.0 |
Carcinogens/*pharmacology | 2 | 3.0 |
Oligodeoxyribonucleotides | 5 | 0.0 |
*Trans-Activators | 2 | 0.0 |
Mitogen-Activated Protein Kinase 1 | 2 | 1.0 |
Oogenesis | 2 | 20.0 |
Starfish | 4 | 50.0 |
Cell Extracts | 2 | 1.0 |
DNA Replication/*physiology | 2 | 5.0 |
Liver Neoplasms/metabolism | 2 | 2.0 |
Sequence Analysis | 2 | 0.0 |
Cross Reactions | 3 | 0.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Cyclins/isolation & purification/*metabolism | 6 | 100.0 |
Deferoxamine/*pharmacology | 2 | 25.0 |
Cyclins/analysis | 3 | 7.0 |
Prostaglandins A/*pharmacology | 2 | 33.0 |
Escherichia coli | 4 | 0.0 |
Magnetic Resonance Spectroscopy | 2 | 0.0 |
*Protein Conformation | 3 | 1.0 |
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 0.0 |
Thermodynamics | 2 | 0.0 |
Enzyme Inhibitors/metabolism/*pharmacology | 2 | 11.0 |
Cell Cycle Proteins/analysis | 4 | 14.0 |
Gene Expression Regulation, Neoplastic/physiology | 2 | 1.0 |
Oncogene Proteins/genetics/metabolism | 3 | 9.0 |
Saccharomyces cerevisiae/genetics/metabolism | 2 | 1.0 |
Antimetabolites, Antineoplastic/pharmacology | 3 | 3.0 |
Subcellular Fractions | 2 | 1.0 |
Cell Cycle Proteins/*genetics | 2 | 1.0 |
Stomach Neoplasms/*genetics | 2 | 1.0 |
Protein-Tyrosine Kinase/*antagonists & inhibitors | 2 | 1.0 |
Altruism | 4 | 12.0 |
France/epidemiology | 4 | 2.0 |
Health Personnel | 4 | 22.0 |
Health Services/standards | 4 | 36.0 |
Hospital Departments/statistics & numerical data | 4 | 36.0 |
Internet/instrumentation | 4 | 36.0 |
Surgery/manpower/*standards/*statistics & numerical data | 4 | 36.0 |
United States | 2 | 0.0 |
Neurons/*metabolism/pathology | 2 | 3.0 |
Suppression, Genetic | 2 | 3.0 |
Gene Expression Regulation/physiology | 2 | 0.0 |
Baculoviridae/genetics/metabolism | 2 | 22.0 |
Androgens/*physiology | 2 | 4.0 |
Anilides/pharmacology | 2 | 7.0 |
RNA Interference | 3 | 1.0 |
Restriction Mapping | 2 | 0.0 |
Alkaloids/pharmacology | 2 | 1.0 |
Proto-Oncogene Proteins c-bcl-2 | 3 | 1.0 |
Staurosporine | 3 | 3.0 |
Glutathione Transferase/genetics/metabolism | 2 | 1.0 |
Peptides/genetics/*metabolism | 2 | 6.0 |
Interphase/*physiology | 2 | 18.0 |
Image Processing, Computer-Assisted | 2 | 0.0 |
Histones/genetics | 2 | 9.0 |
Oncogene Proteins/*biosynthesis/genetics | 2 | 25.0 |
*Genes, Viral | 2 | 1.0 |
Mitosis/*physiology | 2 | 2.0 |
Oncogene Proteins/genetics | 3 | 4.0 |
Cell Movement | 2 | 0.0 |
Antineoplastic Agents/chemical synthesis/chemistry/pharmacology | 4 | 44.0 |
CDC2-CDC28 Kinases/*antagonists & inhibitors | 5 | 83.0 |
Herpesvirus 4, Human/*physiology | 3 | 5.0 |
Oncogene Proteins, Viral/*metabolism | 4 | 11.0 |
Computer Simulation | 2 | 0.0 |
Cyclins/*chemistry | 2 | 50.0 |
*Models, Molecular | 2 | 1.0 |
Transcription Factor TFIIB | 2 | 2.0 |
Transcription Factors/chemistry | 2 | 6.0 |
MAP Kinase Signaling System/physiology | 2 | 2.0 |
Trans-Activators/*metabolism | 5 | 0.0 |
Purines/chemistry/pharmacology | 2 | 66.0 |
*Protein-Tyrosine-Phosphatase | 2 | 15.0 |
Growth Inhibitors/physiology | 2 | 8.0 |
CDC2 Protein Kinase/biosynthesis/genetics | 2 | 66.0 |
Enzyme Inhibitors/chemistry/*pharmacology | 2 | 6.0 |
Carrier Proteins/pharmacology | 2 | 3.0 |
Indoles/pharmacology | 2 | 0.0 |
Maleimides/pharmacology | 2 | 2.0 |
RNA, Messenger/analysis/biosynthesis | 2 | 0.0 |
Cyclin-Dependent Kinases/antagonists & inhibitors/*chemistry | 2 | 100.0 |
Adenosine Triphosphate/chemistry/metabolism | 3 | 30.0 |
Recombinant Proteins/chemistry | 2 | 0.0 |
Threonine/chemistry | 3 | 4.0 |
*Chromosomes, Human, Pair 12 | 2 | 0.0 |
CDC2 Protein Kinase/genetics | 2 | 14.0 |
*Phosphoproteins | 3 | 2.0 |
Oocytes/physiology | 2 | 1.0 |
DNA, Viral | 2 | 1.0 |
Viral Matrix Proteins/genetics/*metabolism | 2 | 10.0 |
Subcellular Fractions/metabolism | 2 | 0.0 |
Oncogene Proteins/genetics/*metabolism | 2 | 4.0 |
Glycogen Synthase Kinase 3/*antagonists & inhibitors | 2 | 66.0 |
Homeostasis | 2 | 0.0 |
Chromatin Immunoprecipitation | 2 | 5.0 |
Tomography, X-Ray Computed | 2 | 0.0 |
Centrifugation, Density Gradient | 3 | 0.0 |
Cyclins/analysis/*metabolism | 2 | 50.0 |
CDC2 Protein Kinase/physiology | 2 | 13.0 |
RNA/analysis | 2 | 0.0 |
Peptides/chemistry | 2 | 0.0 |
Proliferating Cell Nuclear Antigen | 3 | 1.0 |
Cyclins/metabolism/physiology | 2 | 50.0 |
Phosphoric Monoester Hydrolases/genetics/*metabolism | 2 | 4.0 |
Protein Kinases/*genetics | 4 | 3.0 |
Protein Kinases/isolation & purification/*metabolism | 4 | 20.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 3 | 0.0 |
CDC2 Protein Kinase/isolation & purification/*metabolism | 3 | 60.0 |
Protein Kinases/genetics | 2 | 3.0 |
Phosphopeptides/isolation & purification | 3 | 16.0 |
Down-Regulation/*drug effects | 2 | 3.0 |
Fibroblasts/*cytology | 2 | 6.0 |
Protein Kinases/genetics/*metabolism | 3 | 3.0 |
Insects | 3 | 1.0 |
Testis/metabolism | 2 | 0.0 |
*Viral Proteins | 2 | 1.0 |
CDC2-CDC28 Kinases/biosynthesis/genetics | 2 | 100.0 |
Cyclins/genetics/immunology/*metabolism | 2 | 100.0 |
Colonic Neoplasms/*pathology | 2 | 2.0 |
Cyclin A/biosynthesis/genetics | 2 | 40.0 |
Cyclin E/biosynthesis/genetics | 2 | 66.0 |
Protein p53/biosynthesis/genetics | 2 | 4.0 |
Adenovirus Early Proteins | 3 | 4.0 |
Oncogene Proteins, Viral/metabolism | 2 | 10.0 |
Cyclins/drug effects | 3 | 100.0 |
Butyrates/pharmacology | 2 | 5.0 |
Recombinant Proteins/genetics/isolation & purification/metabolism | 2 | 2.0 |
Response Elements | 2 | 0.0 |
Enzyme Inhibitors/*pharmacology/therapeutic use | 2 | 6.0 |
Carcinoma/*pathology | 2 | 3.0 |
Tumor Suppressor Proteins/genetics/metabolism | 3 | 9.0 |
CDC2-CDC28 Kinases/antagonists & inhibitors | 2 | 66.0 |
Membrane Glycoproteins/pharmacology | 2 | 3.0 |
Transcription Factor AP-1/metabolism | 2 | 0.0 |
Phosphoric Monoester Hydrolases/metabolism | 2 | 2.0 |
Interleukin-4/pharmacology | 2 | 0.0 |
Electrophoresis, Gel, Two-Dimensional/*methods | 2 | 10.0 |
*Motor Vehicles | 2 | 8.0 |
Myocardial Infarction/*etiology | 2 | 6.0 |
Patient Transfer | 2 | 8.0 |
*Transportation of Patients | 2 | 8.0 |
Vehicle Emissions/*adverse effects | 2 | 6.0 |
Protein Interaction Mapping | 2 | 1.0 |
Neoplasm Proteins/genetics/metabolism | 2 | 1.0 |
Flow Cytometry/methods | 2 | 0.0 |
Caffeine/pharmacology | 2 | 2.0 |
Virus Replication | 3 | 0.0 |
*Active Transport, Cell Nucleus | 2 | 5.0 |
Tumor Suppressor Proteins/*biosynthesis | 4 | 16.0 |
Transcription Factors | 2 | 2.0 |
Trypsin/pharmacology | 2 | 1.0 |
Proto-Oncogene Proteins/*antagonists & inhibitors/metabolism | 2 | 10.0 |
Pyrazoles/*chemical synthesis/chemistry/pharmacology | 2 | 66.0 |
Kidney Neoplasms/*pathology | 3 | 9.0 |
Reactive Oxygen Species/metabolism | 2 | 0.0 |
RNA, Messenger/drug effects/metabolism | 2 | 1.0 |
Gene Expression Regulation, Leukemic/drug effects | 3 | 12.0 |
Retinoblastoma Protein/genetics | 2 | 5.0 |
Acute Disease | 2 | 0.0 |
JNK Mitogen-Activated Protein Kinases | 2 | 0.0 |
Carcinoma, Renal Cell/*pathology | 2 | 12.0 |
Enzyme Inhibitors/chemistry/pharmacology | 3 | 12.0 |
Glioma/*pathology | 2 | 3.0 |
Cell Culture Techniques/methods | 2 | 0.0 |
Monensin/*pharmacology | 2 | 50.0 |
Cyclin D1/analysis/metabolism | 2 | 66.0 |
*Arabidopsis Proteins | 2 | 2.0 |
Cyclin D1/genetics | 2 | 3.0 |
Ubiquitin-Protein Ligases | 2 | 0.0 |
Blood Proteins/metabolism | 2 | 0.0 |
Active Transport, Cell Nucleus | 2 | 0.0 |
Tumor Cells, Cultured/cytology/drug effects | 2 | 5.0 |
